Announcements
- argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
- argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
- argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
- argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
- argenx Appoints Ana Cespedes to Board of Directors
- argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
- argenx Enters Into Agreement To Acquire Priority Review Voucher
- argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
- argenx to Present at Upcoming Investor Conferences
- argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
More ▼
Key statistics
On Friday, argenx SE (ARGX:NSQ) closed at 380.90, -6.63% below its 52-week high of 407.93, set on Dec 01, 2022.
52-week range
Markit short selling activity
Open | 371.85 |
---|---|
High | 385.27 |
Low | 371.85 |
Bid | 381.00 |
Offer | 571.35 |
Previous close | 382.10 |
Average volume | 201.30k |
---|---|
Shares outstanding | 55.40m |
Free float | 54.66m |
P/E (TTM) | -- |
Market cap | 21.21bn USD |
EPS (TTM) | -17.47 USD |
Data delayed at least 15 minutes, as of Jan 27 2023 21:00 GMT.
More ▼